NCT03844815进行中（未招募）1 期
Phase 1 Study of Venetoclax in Combination With Decitabine 10-Day Regimen in Subjects With Acute Myeloid Leukemia
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- The rate of dose limiting toxicity (DLT)
研究概览
简要总结
The main purpose of this study is to learn about the safety and tolerability of an experimental drug, Venetoclax, when it is given along with Decitabine in subjects diagnosed with acute myeloid leukemia (AML).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Phase 1: Dose Escalation Phase
- •High risk AML, including any of the following:
- •Relapsed or refractory disease
- •TP53 mutant AML
- •Adverse risk cytogenetics including any of the following: 3 or more abnormalities; deletions involving chromosomes 5, 7, or 17; abnormalities in chromosome 11 involving MLL; t(6;9); inv(3) or t(3;3)
- •ECOG performance status 0-2
- •Age 18 years or older
- •Adequate organ function as defined by all of the following:
- •Creatinine clearance ≥30 mL/min, determined by the Cockroft-Gault formula, or measured by a 24 hour urine collection
- •AST and ALT ≤3 x ULN and bilirubin ≤1.5 x ULN (unless considered due to Gilbert's syndrome or of non-hepatic origin i.e. leukemic involvement).
- •Patients must be at least 2 weeks from major surgery, radiation therapy, or participation in other investigational trials, and must have recovered from clinically significant toxicities related to these prior treatments.
- •Patients must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the i initiation of any screening or study specific procedures.
- •Female patients of childbearing potential must have negative results for a pregnancy test
- •Patients must be willing to use appropriate contraception
- •Phase 2: Dose Expansion Phase During the Phase 2 portion of the study, the subject population will be limited to patients with previously untreated AML with a mutation in TP
- •All other inclusion criteria described above will apply.
排除标准
- •- Key exclusion criteria (apply to both Phase 1 and Phase 2 portions of the study):
- •Concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in this protocol
- •Patients suitable for and willing to receive intensive induction chemotherapy
- •Use of investigational agents and/or anticancer therapy within 2 weeks of study entry (with the exception of hydroxyurea, which is permitted before and during Cycle 1 of therapy until D10, at the discretion of the investigator)
- •Prior treatment with venetoclax, decitabine, or azacitidine
- •Diagnosis of acute promyelocytic leukemia
- •Pregnant or breastfeeding patients
- •Patient known to be positive for HIV
- •Known CNS involvement with AML
- •Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
- •Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
- •Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.
- •An active second cancer that requires treatment within 6 months of study entry
- •Cardiac history including the following:
- •History of CHF requiring treatment or Ejection Fraction ≤ 50%
- •Subject has a cardiovascular disability status of New York Heart Association
- •Class > 2, defined as:
- •i. Cardiac disease in which patients are comfortable at rest but ordinary physical activity ii. Results in fatigue, palpitations, dyspnea, or anginal pain c. Chronic stable angina
- •Treatment with any of the following within 7 days prior to the first dose of study drug:
- •Steroid therapy for anti-neoplastic intent
- •Moderate or strong cytochrome P450 3A (CYP3A) inducers
- •Administration or consumption of any of the following within 3 days prior to the first dose of study drug:
- •Grapefruit or grapefruit products
- •Seville oranges (including marmalade containing Seville oranges)
研究组 & 干预措施
Treatment
Experimental
Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21
Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21
During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21
干预措施: Decitabine (Drug)
Treatment
Experimental
Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21
Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21
During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21
干预措施: Venetoclax (Drug)
结局指标
主要结局
The rate of dose limiting toxicity (DLT)
时间窗: 24 months
Determine the rate of subjects who experience a dose limiting toxicity and the maximum tolerable dose
次要结局
- Levels of toxicity with combination regimen(24 months)
- Assessment of Overall Survival(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin LymphomaNon-hodgkin LymphomaNCT03713580Case Comprehensive Cancer Center25
招募中
2 期
Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAMLSecondary Acute Myeloid LeukemiaNCT05513131The First Affiliated Hospital with Nanjing Medical University30
招募中
1 期
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaMantle Cell LymphomaNCT03523975City of Hope Medical Center28
进行中（未招募）
1 期
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisAL AmyloidosisNCT05451771Columbia University53
进行中（未招募）
1 期
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)ALL, Recurrent, AdultNCT05182385Goethe University30